GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.

GSK plc American Depositary Shares (Each representing two)

First Nordic Metals ( ($TSE:GSKR) ) just unveiled an update. First Nordic Metals issued a regulatory-style update largely composed of boilerplate l...

First Nordic Metals Issues Extensive Regulatory and Risk Disclosure Update

U.S. stocks ended the week lower as pressure from rates and commodities weighed on risk appetite. The Dow Jones Industrial Average (DJIA) fell 0.36...

The Week That Was, The Week Ahead: Macro and Markets, Feb. 1

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. Study Overview GlaxoSmithKline (GSK) is launching a Phase 1 trial title...

GSK Advances Liver Disease Pipeline With New Efimosfermin Alfa Trial

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline today and set a price target of £16.75. Papadakis covers the H...

Deutsche Bank  Remains a Hold on GlaxoSmithKline (GSK)

Bank of America Securities analyst Graham Parry initiated coverage with a Hold rating on GlaxoSmithKline today and set a price target of £19.00. Ac...

GlaxoSmithKline (GSK) Receives a New Rating from Bank of America Securities

J.P. Morgan analyst Zain Ebrahim maintained a Sell rating on GlaxoSmithKline today and set a price target of £17.00. Ebrahim covers the Healthcare ...

GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK has updated the record for its Phase 1 study titled “A Randomized, ...

GSK Halts Early-Stage Sickle Cell Study, Tweaking the Risk Profile of Its Rare Disease Pipeline

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK Update: Phase 3 Dementia Study With Alector Comes to an Early End S...

GSK and Alector Phase 3 Dementia Trial Ends Early: What Investors Need to Know

UBS analyst Matthew Weston maintained a Hold rating on GlaxoSmithKline today and set a price target of p1,940.00. According to TipRanks, Weston is ...

UBS Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £17.80. In addition to Barclays, Glax...

Barclays Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has disclosed several transactions in which senior leaders, including non-...

GSK Executives Increase Holdings via Dividend Reinvestment in ADSs

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline, with a price target of £16.75. Papad...

Deutsche Bank  Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

In a report released today, Matthew Weston from UBS maintained a Hold rating on GlaxoSmithKline, with a price target of p1,940.00. Weston covers th...

UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Barclays analyst Shirley Chen maintained a Sell rating on GlaxoSmithKline yesterday. The company’s shares closed yesterday at p1,848.00. Chen cover...

Barclays Remains a Sell on GlaxoSmithKline (GSK)

The latest announcement is out from GlaxoSmithKline ( ($GB:GSK) ). GSK plc disclosed that President of Corporate Development David Redfern and Seni...

GSK Executives Reinvest Dividends in Additional Company Shares

In a report released today, Sarita Kapila from Morgan Stanley maintained a Sell rating on GlaxoSmithKline, with a price target of p1,600.00. Kapila...

GlaxoSmithKline (GSK) Gets a Sell from Morgan Stanley

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK plc has disclosed a series of transactions in which senior executives and a person...

GSK Executives Reinvest Dividends into Company Shares via Reward Plan

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. Study Overview – GlaxoSmithKline (GSK) is launching a first-time-in-hum...

GSK Advances New First-in-Human Prostate Cancer Drug Into Early Clinical Testing

Tempus AI’s ($TEM) preliminary results show its total contract value (TCV) surpassed $1.1 billion, marking the highest level in its history. The up...

Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges

Johnson & Johnson ($JNJ) reached a significant agreement with the Trump administration to lower drug prices for Americans while securing exemptions...

Johnson & Johnson Wins Tariff Relief from Trump in a Drug Pricing Deal

In a report released yesterday, Michael Leuchten from Jefferies reiterated a Buy rating on GlaxoSmithKline, with a price target of p2,100.00. The c...

GlaxoSmithKline (GSK) Receives a Buy from Jefferies

In a report released yesterday, Michael Leuchten from Jefferies maintained a Buy rating on GlaxoSmithKline, with a price target of $55.60. The comp...

J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

Shares in pharmaceuticals giant GSK ($GSK) edged higher today on hopes that it is getting closer to finding a $2 billion cure for the deadly Hepati...

GSK Stock (GSK) Climbs as it Hails Potential $2B Cure for Deadly Hepatitis B Virus

UBS analyst Matthew Weston maintained a Hold rating on GlaxoSmithKline yesterday. The company’s shares closed today at p1,899.50. Weston covers the...

UBS Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK’s latest oncology trial update centers on a study titled “A Phase 1...

GSK Advances Targeted Cancer Combo Trial, Keeping Its Oncology Pipeline in Focus

Barclays analyst Shirley Chen downgraded GlaxoSmithKline to a Sell today and set a price target of £17.80. According to TipRanks, Chen is a 3-star ...

GlaxoSmithKline (GSK) was downgraded to a Sell Rating at Barclays

GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK has secured European Commission approval for a new prefilled syringe presentation of its ...

GSK Wins EU Approval for Prefilled Syringe Version of Shingrix

Berenberg Bank analyst maintained a Hold rating on GlaxoSmithKline yesterday and set a price target of $43.00. The company’s shares closed yesterda...

Berenberg Bank Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has disclosed that, as of 31 December 2025, its issued share capital comprised 4,315,445,02...

GSK Confirms Total Voting Rights at Year-End 2025

GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK plc has disclosed that David Redfern, President of Corporate Development, and Victoria Wh...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GSK	$53.22	+1.43%	3.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GSK	$53.22	+1.4%	3.59M
3
4
5
6

GSK

GSK

Get GSK plc American Depositary Shares (Each representing two) Data in Excel

Get GSK plc American Depositary Shares (Each representing two) Data in Excel